DE3687763D1 - Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen. - Google Patents

Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.

Info

Publication number
DE3687763D1
DE3687763D1 DE8686200766T DE3687763T DE3687763D1 DE 3687763 D1 DE3687763 D1 DE 3687763D1 DE 8686200766 T DE8686200766 T DE 8686200766T DE 3687763 T DE3687763 T DE 3687763T DE 3687763 D1 DE3687763 D1 DE 3687763D1
Authority
DE
Germany
Prior art keywords
oxidation
muteine
muteins
resistant
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686200766T
Other languages
English (en)
Other versions
DE3687763T2 (de
Inventor
Kirston Edward Koths
Robert Forgan Halenbeck
Michael Allan Innis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Application granted granted Critical
Publication of DE3687763D1 publication Critical patent/DE3687763D1/de
Publication of DE3687763T2 publication Critical patent/DE3687763T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Dental Preparations (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Peptides Or Proteins (AREA)
DE8686200766T 1985-01-18 1986-01-17 Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen. Expired - Lifetime DE3687763T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69259685A 1985-01-18 1985-01-18
US81065685A 1985-12-17 1985-12-17

Publications (2)

Publication Number Publication Date
DE3687763D1 true DE3687763D1 (de) 1993-03-25
DE3687763T2 DE3687763T2 (de) 1993-06-09

Family

ID=36846757

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686200766T Expired - Lifetime DE3687763T2 (de) 1985-01-18 1986-01-17 Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.

Country Status (7)

Country Link
EP (1) EP0200280B1 (de)
JP (1) JP2595206B2 (de)
AT (1) ATE85810T1 (de)
AU (2) AU5245186A (de)
CA (1) CA1340265C (de)
DE (1) DE3687763T2 (de)
NZ (1) NZ214854A (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
CA1340265C (en) * 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
AU595864B2 (en) * 1986-03-14 1990-04-12 Otsuka Pharmaceutical Co., Ltd. Il-1 alpha derivatives and drugs
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
EP0378666A4 (en) * 1988-07-05 1992-01-22 Amgen Inc. Interleukin ii analogs
EP1199355B1 (de) * 1999-06-29 2007-03-14 National Institute of Advanced Industrial Science and Technology Schwefelfreie enzyme
EP1694360B1 (de) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat-abstossung
CA2712432C (en) * 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
EP2683395B1 (de) 2011-03-11 2018-08-01 Assistance Publique - Hôpitaux de Paris Verwendung von niedrigdosiertem il-2 zur behandlung von typ i diabetes
WO2014206899A1 (en) 2013-06-25 2014-12-31 Icm (Institut Du Cerveau Et De La Moelle Épinière) Boosting treg cells for treating alzheimer disease and related disorders
EP2918285A1 (de) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 zur Behandlung einer Lebensmittelallergie
RU2573933C1 (ru) * 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
MX2018004883A (es) * 2015-10-22 2018-08-01 Iltoo Pharma Composiciones farmaceuticas de il-2.
EP3475413B1 (de) 2016-06-22 2024-02-14 David Klatzmann Genetisch modifizierte t-lymphozyten
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3752178A1 (de) 2018-02-16 2020-12-23 Iltoo Pharma Verwendung von interleukin 2 zur behandlung des sjögren-syndroms
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP3880838A4 (de) 2018-11-15 2022-11-02 The Board of Trustees of the Leland Stanford Junior University Zusammensetzungen und verfahren zur prognose und klassifizierung von präeklampsie
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
JP2023505590A (ja) 2019-12-12 2023-02-09 イルトゥー・ファルマ インターロイキン２キメラ構築物
US20230090069A1 (en) 2020-03-06 2023-03-23 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
WO2023057588A1 (en) 2021-10-06 2023-04-13 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2544348C3 (de) * 1975-10-03 1979-12-13 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen L-Leucin-13-Motilin, Verfahren zu dessen Herstellung und dasselbe enthaltendes Mittel
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS605600B2 (ja) * 1982-10-25 1985-02-12 工業技術院長 新規なポリペプチド
ATE53220T1 (de) * 1983-03-07 1990-06-15 Hoffmann La Roche Polypeptide.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE81141B1 (en) 1983-06-24 2000-04-05 Genencor Int Procaryotic carbonyl hydrolases
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
DE3419995A1 (de) * 1984-05-29 1985-12-05 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
CA1340265C (en) * 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins

Also Published As

Publication number Publication date
EP0200280A2 (de) 1986-11-05
ATE85810T1 (de) 1993-03-15
AU5245186A (en) 1986-07-31
NZ214854A (en) 1989-07-27
DE3687763T2 (de) 1993-06-09
JPS61224985A (ja) 1986-10-06
JP2595206B2 (ja) 1997-04-02
EP0200280A3 (en) 1988-08-24
AU6484686A (en) 1987-02-05
AU585084B2 (en) 1989-06-08
EP0200280B1 (de) 1993-02-17
CA1340265C (en) 1998-12-15

Similar Documents

Publication Publication Date Title
DE3687763D1 (de) Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.
DK481383D0 (da) Syntetisk mutein af et biologisk aktivt protein, gen kodende for samme, vektor omfattende dette gen, vaertcelle transformeret med denne vektor samt fremgangsmader til fremstilling af muteinet og genet kodende herfor
ATE246246T1 (de) Herstellung von hämoglobin und analogen davon in nicht-erythrozytzellen
DE3382789T2 (de) Tierische Interferone, Verfahren bei deren Herstellung, dieselben enthaltende Zusammensetzungen, kodierende DNS-Sequenzen hierfür und diese Sequenzen enthaltende Expressionsvektoren und dadurch transformierte Zellen.
ES8603574A1 (es) "procedimiento de tecnologia genetica para preparar secuen- cias parciales del gamma-interferon de humano".
ATE116367T1 (de) Für antitumor-polypeptide kodierende dns, die polypeptide und diese polypeptide enthaltenden antitumor-wirkstoffe.
NO895028D0 (no) Ny chimerisk transformerende vekstfaktor-beta.
ATE152734T1 (de) Bpc-peptide, deren herstellung und verwendung
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
ATE72582T1 (de) Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
ES2081817T3 (es) Polipeptido con secuencias principales repetidas que se fijan en la celula.
EP0249096B1 (de) Reninhemmende Aminosäurederivate.
DE68918399D1 (de) Lymphokine, DNS-Sequenzen, die diese Lymphokine kodieren, und sie enthaltende pharmazeutische Zusammensetzungen.
ATE102997T1 (de) Thymosin und tnf-kodierende dna.
BG60657B2 (en) Human recombinant interleukin-2 muteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US